Inhibition of human immunodeficiency virus replication by RD6-Y664, a novel benzylhydroxylamine derivative

Antiviral Chemistry and Chemotherapy

Volumn 10, Issue 2, 1999, Pages 71-77

  Okamoto, M ^a,b,f   Fujiwara, M ^a,b   Kodama, E ^b   Yamamoto, O ^c   Shigeta, S ^b   Mitsuya, H ^d   Konno, K ^a   Yokota, T ^a   Baba, M ^e  

^a Rational Drug Design Laboratories   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c ASTELLAS PHARMA INC   (Japan)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e KAGOSHIMA UNIVERSITY   (Japan)

^f Sanwa Kagaku Kenkyusho   (Japan)

Author keywords

Anti HIV 1 activity; Benzylhydroxylamine; Structure activity relationship

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; BENZYLHYDROXYLAMINE DERIVATIVE; CD4 ANTIGEN; GLYCOPROTEIN GP 120; RD6 Y664; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION; STRUCTURE ACTIVITY RELATION; VIRUS CULTURE; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0032921726     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029901000203     Document Type: Article

References (22)

1. Baba M, Shigeta S, Yuasa S, Takashima H, Sekiya K, Ubasawa M, Tanaka H, Miyasaka T, Walker RT & De Clercq E (1994) Preclinical evaluation of MKC-422, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrobiral Agents Chemotherapy 38:688-692.
2. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, Reingold A & Manos MM (1991) Genital human papillomavirus infection in female university students as determined by PCR-based method. Journal of the American Medical Association 265:472-477.
3. + cell model of chronic infection. Journal of Virology 65:4645-4653.
4. 50, synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics. In Computer Software for IBM-PC and Manual, pp. 19-32. Cambridge; Elsevier-Biosoft.
5. Chou T-C & Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 22:27-55.
6. Cohen J (1997) The daunting challenge of keeping HIV suppressed. Science 277:32-33.
7. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichimn RC, Hooper C & Corey L, for the AIDS Clinical Trials Group (1996) Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. New England Journal of Medicine 334:1011-1017.
8. De Clercq E (1995) Antiviral therapy for human immunodeficiency virus infections. Clinical Microbiology Reviews 8:200-239.
9. Fujiwara M, Okamoto M, Ijichi K, Tokuhisa K, Hanasaki Y, Katsuura K, Uemura D, Shigeta S, Konno K, Yokota T and Baba M (1998) Upregulation of HIV-1 replication in chronically infected cells by ingenol derivatives. Archives of Virology 143:2003-2010.
10. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Nusinoff Lehrman S, Bolognesi DP, Broder S, Mitsuya H & Barry DW (1986) Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proceedings of the National Academy of Sciences, USA 83:8333-8337.
11. Gao W-Y, Johns DG, Chokekijchai S & Mitsuya H (1995) Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 92:8333-8337.
12. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA & Chodakewitz JA (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 337:734-739.
13. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA & Fischl MA, for the AIDS Clinical Trials Group 320 Study Team (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 337:725-733.
14. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM & Markowitz M (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
15. Kikukawa R, Koyanagi Y, Harada S, Kobayashi N, Hatanaka M & Yamamoto N (1986) Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line molt-4. Journal of Virology 57:1159-1162.
16. Kimpton J & Emerman M (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. Journal of Virology 66:2232-2239.
17. Lipsky JJ (1996) Antiretroviral drugs for AIDS. Lancet 348:800-803.
18. Moore JP, Trkola A & Dragic T (1997) Co-receptors for HIV-1 entry. Current Opinion in Immunology 9:551-562.
19. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J & De Clercq E (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virology Methods 20:309-321.
20. Shirasaka T, Kavlick MF, Ueno T, Gao W-Y, Kojima E, Alcaide ML, Chokekijchai S, Roy BM, Arnold E, Yarchoan R & Mitsuya H (1995) Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proceedings of the National Academy of Sciences, USA 92:2398-2402.
21. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS & Shaw GM (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
22. Yuasa S, Sadakata Y, Takashima H, Sekiya K, Inouye N, Ubasawa M & Baba M (1993) Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442. Molecular Pharmacology 44:895-900.